Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro

Endocrine-Related Cancer

Volumn 16, Issue 3, 2009, Pages 1017-1027

  Gorshtein, Alexander ^a,b,c   Rubinfeld, Hadara ^a,b   Kendler, Efrat ^a,b   Theodoropoulou, Marily ^d   Cerovac, Vesna ^d   Stalla, Günter K ^d   Cohen, Zvi R ^b,e   Hadani, Moshe ^b,e   Shimon, Ilan ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c MEIR MEDICAL CENTER   (Israel)

^d MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^e SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN D3; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN E; EVEROLIMUS; RAPAMYCIN; S6 KINASE; TRANSCRIPTION FACTOR E2F;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL VIABILITY; COMPLEX FORMATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; GROWTH HORMONE SECRETING ADENOMA; IN VITRO STUDY; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RAT;

ADENOMA; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN D3; DRUG EVALUATION, PRECLINICAL; E2F TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIROLIMUS; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED;

EID: 72749102942     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-08-0269     Document Type: Article

References (35)

1. Altomare DA & Testa JR 2005 Perturbations of the AKT signaling pathway in human cancer. Oncogene 24 7455-7464. (Pubitemid 41637985)
2. Bamberger CM, Fehn M, Bamberger AM, Ludecke DK, Beil FU, Saeger W & Schulte HM 1999 Reduced expression levels of the cell-cycle inhibitor p27Kip1 in human pituitary adenomas. European Journal of Endocrinology 140 250-255. (Pubitemid 29155584)
3. Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O'Reilly T, Natt F, Hall J, Lane HA & Thomas G 2005 The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120 747-759. (Pubitemid 40568794)
4. Cantley LC & Neel BG 1999 New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. PNAS 96 4240-4245.
5. Chiang GG & Abraham RT 2005 Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. Journal of Biological Chemistry 280 25485-25490. (Pubitemid 40962253)
6. Daly AF, Burlacu MC, Livadariu E & Beckers A 2007 The epidemiology and management of pituitary incidentalomas. Hormone Research 68 195-198.
7. Faivre S, Kroemer G & Raymond E 2006 Current development of mTOR inhibitors as anticancer agents. Nature Reviews. Drug Discovery 5 671-688. (Pubitemid 44151605)
8. Gaben AM, Saucier C, Bedin M, Barbu V & Mester J 2004 Rapamycin inhibits cdk4 activation, p 21(WAF1/CIP1) expression and G1-phase progression in transformed mouse fibroblasts. International Journal of Cancer 108 200-206.
9. Garcia-Morales P, Hernando E, Carrasco-Garcia E, Menendez-Gutierrez MP, Saceda M & Martinez-Lacaci I 2006 Cyclin D3 is down-regulated by rapamycin in HER-2-overexpressing breast cancer cells. Molecular Cancer Therapeutics 5 2172-2181. (Pubitemid 44530453)
10. Hashemolhosseini S, Nagamine Y, Morley SJ, Desrivieres S, Mercep L & Ferrari S 1998 Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. Journal of Biological Chemistry 273 14424-14429. (Pubitemid 28319162)
11. Hipp S, Ringshausen I, Oelsner M, Bogner C, Peschel C & Decker T 2005 Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells. Haematologica 90 1433-1434. (Pubitemid 41503659)
12. Kawamata S, Sakaida H, Hori T, Maeda M & Uchiyama T 1998 The upregulation of p27Kip1 by rapamycin results in G1 arrest in exponentially growing T-cell lines. Blood 91 561-569. (Pubitemid 28053379)
13. Kawashima K, Yamakawa K & Arita J 2000 Involvement of phosphoinositide-3-kinase and p70 S6 kinase in regulation of proliferation of rat lactotrophs in culture. Endocrine 13 385-392. (Pubitemid 32108068)
14. Kenerson H, Dundon TA & Yeung RS 2005 Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. Pediatric Research 57 67-75. (Pubitemid 40039895)
15. LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A & Harlow E 1997 New functional activities for the p21 family of CDK inhibitors. Genes and Development 11 847-862. (Pubitemid 27175292)
16. Lidhar K, Korbonits M, Jordan S, Khalimova Z, Kaltsas G, Lu X, Clayton RN, Jenkins PJ, Monson JP, Besser GM et al. 1999 Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors. Journal of Clinical Endocrinology and Metabolism 84 3823-3830. (Pubitemid 30645248)
17. Lu C, Willingham MC, Furuya F & Cheng SY 2008 Activation of phosphatidylinositol 3-kinase signaling promotes aberrant pituitary growth in a mouse model of thyroid-stimulating hormone-secreting pituitary tumors. Endocrinology 149 3339-3345. (Pubitemid 351919619)
18. Luo Y, Marx SO, Kiyokawa H, Koff A, Massague J & Marks AR 1996 Rapamycin resistance tied to defective regulation of p27Kip1. Molecular and Cellular Biology 16 6744-6751. (Pubitemid 26389733)
19. Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew D, Kleinberg D & Barkan A 2005 A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. Journal of Clinical Endocrinology and Metabolism 90 4405-4410. (Pubitemid 41058228)
20. Musat M, Korbonits M, Kola B, Borboli N, Hanson MR, Nanzer AM, Grigson J, Jordan S, Morris DG, Gueorguiev M et al. 2005 Enhanced protein kinase B/Akt signalling in pituitary tumours. Endocrine-Related Cancer 12 423-433. (Pubitemid 40896456)
21. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY & Nakayama K 1996 Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85 707-720. (Pubitemid 126334351)
22. Ooi GT, Tawadros N & Escalona RM 2004 Pituitary cell lines and their endocrine applications. Molecular and Cellular Endocrinology 228 1-21. (Pubitemid 39482516)
23. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL et al. 2006 mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Research 66 1500-1508. (Pubitemid 43259931)
24. Qian X, Jin L, Grande JP & Lloyd RV 1996 Transforming growth factor-beta and p27 expression in pituitary cells. Endocrinology 137 3051-3060. (Pubitemid 26192204)
25. Rubinfeld H, Hadani M, Barkai G, Taylor JE, Culler MD & Shimon I 2006 Cortistatin inhibits growth hormone release from human fetal and adenoma pituitary cells and prolactin secretion from cultured prolactinomas. Journal of Clinical Endocrinology and Metabolism 91 2257-2263. (Pubitemid 43855015)
26. Sehgal SN, Baker H & Vezina C 1975 Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. Journal of Antibiotics 28 727-732.
27. Sherr CJ 2000 The Pezcoller lecture: cancer cell cycles revisited. Cancer Research 60 3689-3695.
28. Sherr CJ & Roberts JM 1995 Inhibitors of mammalian G1 cyclin-dependent kinases. Genes and Development 9 1149-1163.
29. Simpson L & Parsons R 2001 PTEN: life as a tumor suppressor. Experimental Cell Research 264 29-41.
30. Stromberg T, Dimberg A, Hammarberg A, Carlson K, Osterborg A, Nilsson K & Jernberg-Wiklund H 2004 Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood 103 3138-3147. (Pubitemid 38451692)
31. Vivanco I & Sawyers CL 2002 The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nature Reviews. Cancer 2 489-501. (Pubitemid 37328931)
32. Wanner K, Hipp S, Oelsner M, Ringshausen I, Bogner C, Peschel C & Decker T 2006 Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. British Journal of Haematology 134 475-484. (Pubitemid 44141713)
33. Weinberg RA 1995 The retinoblastoma protein and cell cycle control. Cell 81 323-330.
34. Wera S, Belayew A & Martial JA 1995a Rapamycin, FK506 and cyclosporin A inhibit human prolactin gene expression. FEBS Letters 358 158-160.
35. Wera S, Zheng L, Hooghe-Peters EL, Belayew A, Martial JA & Velkeniers B 1995b Cyclosporin A, rapamycin and FK506 decrease prolactin release from rat pituitary cells in primary culture. Endocrine Research 21 623-633.